Shield TherapeuticsSTU:1JS Current Ratio is 0.90 as of Dec. 2025, which is 61% below its 10-year median of 2.30. The stock has 5 warning signs investors should review. Among 998 Drug Manufacturers companies, Shield Therapeutics ranks worse than 86.57% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Shield Therapeutics's current ratio for the quarter that ended in Dec. 2025 was 0.90.
Shield Therapeutics has a current ratio of 0.90. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Shield Therapeutics has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Shield Therapeutics's Current Ratio or its related term are showing as below:
STU:1JS'
s Current Ratio Range Over the Past 10 Years
Min: 0.9 Med: 2.3 Max: 5.86
Current: 0.9
During the past 12 years, Shield Therapeutics's highest Current Ratio was 5.86. The lowest was 0.90. And the median was 2.30.
STU:1JS's Current Ratio is ranked worse than 86.57% of 998
companies
in the Drug Manufacturers industry
Industry Median: 1.995
vs STU:1JS: 0.90
Shield Therapeutics (STU:1JS) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Shield Therapeutics Current Ratio Related Terms
Shield Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Shield Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:1JS vs ZTS, UTHR, VTRS: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shield Therapeutics Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Shield Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shield Therapeutics (STU:1JS) has a Current Ratio of 0.90 as of Dec. 2025. This is 61% below median its historical median of 2.30. Over the past decade, Shield Therapeutics' Current Ratio has ranged from 0.90 to 5.86. According to the industry distribution chart, Shield Therapeutics ranks #864 out of 998 companies in the Drug Manufacturers industry, placing it in the top 86.6%.
Is Shield Therapeutics' Current Ratio too high?
Shield Therapeutics' current Current Ratio of 0.90 is 61% below median its 10-year median of 2.30. Over the past 10 years, this metric has ranged from a low of 0.90 to a high of 5.86. The Drug Manufacturers industry median Current Ratio is 2.00. Shield Therapeutics' value of 0.90 is 54.9% below this industry median. Based on the distribution chart, Shield Therapeutics ranks #864 out of 998 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Shield Therapeutics' Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shield Therapeutics ranks #864 out of 998 companies for Current Ratio. This places Shield Therapeutics in the lower half of its industry. The industry median Current Ratio is 2.00. Shield Therapeutics' value of 0.90 is 54.9% below this benchmark. Historically, Shield Therapeutics' own Current Ratio has ranged from 0.90 to 5.86 over the past decade. While the company's 10-year median is 2.30 vs. the industry median of 2.00, Shield Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shield Therapeutics's current Current Ratio of 0.90 is 54.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shield Therapeutics's current Current Ratio is 0.90, which is 61% below median its own 10-year median of 2.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shield Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Shield Therapeutics (STU:1JS) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.09, compared to a current price of €0.07 — trading 24.4% below its estimated fair value. The current Current Ratio is 0.90, which is 61% below median its 10-year median of 2.30 and 54.9% below the Drug Manufacturers industry median of 2.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Shield Therapeutics (STU:1JS), the current Current Ratio is 0.90 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1JS has been successfully added to your 